<div id="subtitle">Vertex Pharmaceuticals to seek regulatory OK for telaprevir hepatitis drug in 2nd half of 2010</div><div><p>Biotechnology company Vertex Pharmaceuticals Inc. said Monday it plans to seek regulatory approval of the experimental hepatitis C drug telaprevir as scheduled during the second half of 2009.</p><p>Telaprevir is one of several potential hepatitis C treatments in development. If approved, it could face competition from Schering-Plough Corp.'s experimental hepatitis C drug boceprevir.</p><p>Meanwhile, the company will tell investors at a conference it expects a loss of less than $650 million in fiscal 2009, versus a loss of $459.9 million in fiscal 2008, or $397.5 million on an adjusted basis.</p><p>Vertex has about $1.3 billion in cash, cash equivalents and marketable securities.</p><p>The company will report 2009 financial results and provide a 2010 outlook on Feb. 4.</p><p>Shares of Vertex rose $1.28, or 3.2 percent, to $41.95 in midday trading.</p><img src="http://admatch-syndication.mochila.com/images/ad.gif?aid=66706216&bid=informcom" /></div><div id="copyright"><div>

Copyright 2010  <a href="http://www.ap.org">AP News</a></div></div>